Recep Tayyip Erdoğan Üniversitesi Kurumsal Akademik Arşivi
DSpace@RTEÜ, Recep Tayyip Erdoğan Üniversitesi tarafından doğrudan ve dolaylı olarak yayınlanan; kitap, makale, tez, bildiri, rapor, araştırma verisi gibi tüm akademik kaynakları uluslararası standartlarda dijital ortamda depolar, Üniversitenin akademik performansını izlemeye aracılık eder, kaynakları uzun süreli saklar ve yayınların etkisini artırmak için telif haklarına uygun olarak Açık Erişime sunar.
Güncel Gönderiler
Clinical and anthropometric correlates of polysomnography-defined severity in obstructive sleep apnea syndrome
(Erciyes Üniversitesi, 2026) Topaloğlu, Elvan Şentürk; Özçelik, Neslihan; Özyurt, Songül; Gümüş, Aziz; Şahin, Ünal
Objective: Obstructive sleep apnea syndrome (OSAS) is a common sleep-related breathing disorder frequently associated with cardiometabolic morbidity. In this retrospective study of 339 adults who underwent polysomnography (PSG) between January 2020 and December 2024, we investigated the relationship between routinely obtained clinical and anthropometric measures-body mass index (BMI), neck circumference (NC), waist circumference (WC), and the Epworth Sleepiness Scale (ESS)-and PSG-defined OSAS severity. Materials and Methods: Adults (>= 18 years) who underwent overnight PSG and had complete clinical and anthropometric data were included. OSAS severity was defined using the apnea-hypopnea index (AHI): no OSA (<5 events/h), mild (5-14.9), moderate (15-29.9), and severe (>= 30). Associations between AHI and clinical or anthropometric measures were assessed using Spearman's correlation analysis. Results: A total of 339 patients were included (mean age 46.1 +/- 12.0 years; 73.2% male; mean BMI 33.2 +/- 6.2 kg/m(2)). The median ESS score was 4 (interquartile range [IQR]: 2-9), and the median AHI was 10.1 (IQR: 6.3-32.2). AHI showed statistically significant but weak correlations with age (r=0.207), weight (r=0.136), NC (r=0.273), and WC (r=0.184), whereas the association with ESS was stronger (r=0.649; all p<0.05). No significant correlations were observed with height or BMI. Patients with moderate-to-severe OSAS had higher NC, WC, ESS scores, symptom burden, and cardiometabolic comorbidities compared to those with normal-to-mild OSAS. Conclusion: NC, WC, and ESS were associated with PSG-defined OSAS severity. However, correlations with age, weight, NC, and WC were weak in magnitude despite statistical significance, while BMI showed limited association. These routinely obtained measures may aid clinical assessment in sleep laboratory populations.
A coupled simulation and modeling of WT-AFPMSG based on ansys software and MATLAB/Simulink for wind energy application
(Institute of Electrical and Electronics Engineers Inc., 2025) Bouhafs, Lina; Tamalouzt, Salah; Şahin, Mustafa Ergin; Bouzida, Ahcene
As global demand for clean and sustainable energy rises, wind turbines have become a crucial solution in the transition to renewable sources. The axial flux permanent magnet synchronous generator (AFPMSG), with its compact design, high power density, and efficiency, is an attractive option for wind energy conversion, especially where space and weight constraints are significant. This article presents the modeling and simulation of a wind turbine system based on an AFPMSG. The process was conducted using ANSYS/Maxwell software for finite element analysis (FEA), starting from a preliminary 2D design obtained with Maxwell's RMxprt module, while MATLAB/Simulink was used to model the wind turbine and implement MPPT for optimized energy extraction. A coupled simulation was implemented by exchanging data from MATLAB/Simulink to Ansys/Maxwell, ensuring continuous data exchange between mechanical and electrical parts and ensuring realistic system behavior. The simulation validated the electromagnetic design and highlighted the effectiveness of coupled simulation for performance testing with power electronics circuits.
Updated global consensus recommendations for risk stratification, treatment initiation, and response monitoring in metabolic dysfunction-associated steatotic liver disease
(W.B. Saunders, 2026) Younossi, Zobair M.; Kalligeros, Markos; Wong, Vincent Wai-Sun; Al-Naamani, Khalid M.; Tacke, Frank; Yılmaz, Yusuf; Henry, Linda
Background & Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) have increased in prevalence alongside the global epidemics of obesity and type 2 diabetes and now represent one of the leading causes of chronic liver disease. Patients with MASLD and significant fibrosis (≥F2) are at increased risk for adverse outcomes. With advances in noninvasive tests (NITs) and the recent approval of resmetirom and semaglutide for noncirrhotic MASH with F2–F3 fibrosis, we provide updated consensus guidance on standardized risk stratification, treatment initiation, and response monitoring. Methods A structured Delphi process was conducted following a systematic updated literature review (January 2025–November 2025), covering the period since publication of the initial consensus recommendations, and included iterative anonymous voting among 40 international experts representing hepatology, gastroenterology, endocrinology, internal medicine, and primary care. Consensus was predefined as ≥70% agreement. Results Forty-two statements were developed; 86% achieved consensus in the first round, and all remaining statements reached consensus after refinement and the second round. The panel endorsed a sequential risk-stratification strategy beginning with Fibrosis-4 Index (FIB-4) as the first-line assessment, followed by vibration-controlled transient elastography or Enhanced Liver Fibrosis (ELF) testing for secondary stratification. Treatment consideration with resmetirom or semaglutide was supported for noncirrhotic MASLD with liver stiffness measurement values of 10 to 20 kPa or ELF values of 9.2 to 11.3, after exclusion of cirrhosis. Upfront combination therapy with both drugs was not recommended. Selection of pharmacologic therapy was to be determined through shared decision-making between patient and provider and individualized according to the patient’s cardiometabolic profile. Treatment response at one year was defined as a ≥30% reduction in liver stiffness or a ≥0.5-point reduction in ELF. Conclusions This updated international consensus provides practical algorithms that integrate most commonly used noninvasive testing with recently approved pharmacologic therapies for MASLD, addressing current variability in clinical practice and supporting standardized implementation of risk-based care.
Hepatitis b vaccination rates and risk factors affecting vaccine response in people living with HIV in Turkey
(Bentham Science Publishers, 2026) Mirza, Arzu; Çabalak, Mehmet; Günal, Özgür; Candevir, Aslıhan; Kayaaslan, Bircan; Yıldız, İlknur Esen; Çakmak, Pınar
Introduction: HIV–HBV coinfection is common among individuals living with HIV; therefore, hepatitis B vaccination is recommended. However, vaccine response rates in people living with HIV are lower than those observed in the healthy population. The aim of this study was to determine HBV vaccination rates and identify risk factors affecting vaccine response in people living with HIV. Materials and Methods: This multicenter, observational, retrospective study included patients over 18 years of age who were diagnosed with HIV infection and followed for at least six months between January 2018 and January 2024. Patients were screened for HBV using HBsAg, Anti-HBc IgG, and Anti-HBs serology, and Anti-HBs levels were measured at least 4–8 weeks after completion of the HBV vaccination schedule. Results: Of 811 people living with HIV, 274 met the inclusion criteria. The median age was 37.5 years (range: 18–75), and 85% were male. The hepatitis B vaccination rate in this cohort was 33.7%. Following the HBV vaccination schedule, vaccine response (Anti-HBs ≥10 IU/L) was observed in 73.4% of individuals. Hypertension and chronic obstructive pulmonary disease (COPD) were identified as independent risk factors affecting vaccine response (p = 0.016 and p = 0.026, respectively). Conclusion: Vaccine response was found to be lower in individuals with hypertension and COPD. These factors should be considered when administering the hepatitis B vaccine to people living with HIV to improve immunization outcomes.
Algorithms in allergy: elevated ige in pediatric patients
(Wiley, 2026) Kolukısa, Burcu; Sefer Arınç, Asena Pınar; Özdemir, Cevdet; Karakoc-Aydiner, Elif
...
